Integrated  ||| S:0 E:11 ||| NNP
community  ||| S:11 E:21 ||| NN
case  ||| S:21 E:26 ||| NN
management  ||| S:26 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
fever  ||| S:40 E:46 ||| NN
in  ||| S:46 E:49 ||| IN
children  ||| S:49 E:58 ||| NNS
under  ||| S:58 E:64 ||| IN
five  ||| S:64 E:69 ||| CD
using  ||| S:69 E:75 ||| VBG
rapid  ||| S:75 E:81 ||| JJ
diagnostic  ||| S:81 E:92 ||| JJ
tests  ||| S:92 E:98 ||| NNS
and  ||| S:98 E:102 ||| CC
respiratory  ||| S:102 E:114 ||| JJ
rate  ||| S:114 E:119 ||| NN
counting ||| S:119 E:127 ||| NN
:  ||| S:127 E:129 ||| :
a  ||| S:129 E:131 ||| DT
multi-country  ||| S:131 E:145 ||| JJ
cluster  ||| S:145 E:153 ||| NN
randomized  ||| S:153 E:164 ||| NN
trial  ||| S:164 E:170 ||| NN
Evidence  ||| S:170 E:179 ||| NN
on  ||| S:179 E:182 ||| IN
the  ||| S:182 E:186 ||| DT
impact  ||| S:186 E:193 ||| NN
of  ||| S:193 E:196 ||| IN
using  ||| S:196 E:202 ||| VBG
diagnostic  ||| S:202 E:213 ||| JJ
tests  ||| S:213 E:219 ||| NNS
in  ||| S:219 E:222 ||| IN
community  ||| S:222 E:232 ||| NN
case  ||| S:232 E:237 ||| NN
management  ||| S:237 E:248 ||| NN
of  ||| S:248 E:251 ||| IN
febrile  ||| S:251 E:259 ||| JJ
children  ||| S:259 E:268 ||| NNS
is  ||| S:268 E:271 ||| VBZ
limited ||| S:271 E:278 ||| VBN
.  ||| S:278 E:280 ||| .
This  ||| S:280 E:285 ||| DT
effectiveness  ||| S:285 E:299 ||| NN
trial  ||| S:299 E:305 ||| NN
conducted  ||| S:305 E:315 ||| VBN
in  ||| S:315 E:318 ||| IN
Burkina  ||| S:318 E:326 ||| NNP
Faso ||| S:326 E:330 ||| NNP
,  ||| S:330 E:332 ||| ,
Ghana ||| S:332 E:337 ||| NNP
,  ||| S:337 E:339 ||| ,
and  ||| S:339 E:343 ||| CC
Uganda ||| S:343 E:349 ||| NNP
,  ||| S:349 E:351 ||| ,
compared  ||| S:351 E:360 ||| VBN
a  ||| S:360 E:362 ||| DT
diagnostic  ||| S:362 E:373 ||| JJ
and  ||| S:373 E:377 ||| CC
treatment  ||| S:377 E:387 ||| NN
package  ||| S:387 E:395 ||| NN
for  ||| S:395 E:399 ||| IN
malaria  ||| S:399 E:407 ||| NN
and  ||| S:407 E:411 ||| CC
pneumonia  ||| S:411 E:421 ||| NN
with  ||| S:421 E:426 ||| IN
presumptive  ||| S:426 E:438 ||| JJ
treatment  ||| S:438 E:448 ||| NN
with  ||| S:448 E:453 ||| IN
anti-malarial  ||| S:453 E:467 ||| JJ
drugs ||| S:467 E:472 ||| NNS
;  ||| S:472 E:474 ||| :
artemisinin  ||| S:474 E:486 ||| JJ
combination  ||| S:486 E:498 ||| NN
therapy  ||| S:498 E:506 ||| NN
( ||| S:506 E:507 ||| -LRB-
ACT ||| S:507 E:510 ||| NNP
) ||| S:510 E:511 ||| -RRB-
.  ||| S:511 E:513 ||| .
We  ||| S:513 E:516 ||| PRP
enrolled  ||| S:516 E:525 ||| VBD
4,216  ||| S:525 E:531 ||| CD
febrile  ||| S:531 E:539 ||| CD
children  ||| S:539 E:548 ||| NNS
between  ||| S:548 E:556 ||| IN
4  ||| S:556 E:558 ||| CD
and  ||| S:558 E:562 ||| CC
59  ||| S:562 E:565 ||| CD
months  ||| S:565 E:572 ||| NNS
of  ||| S:572 E:575 ||| IN
age  ||| S:575 E:579 ||| NN
in  ||| S:579 E:582 ||| IN
2009-2010 ||| S:582 E:591 ||| CD
.  ||| S:591 E:593 ||| .
Compliance  ||| S:593 E:604 ||| NN
with  ||| S:604 E:609 ||| IN
the  ||| S:609 E:613 ||| DT
malaria  ||| S:613 E:621 ||| JJ
rapid  ||| S:621 E:627 ||| JJ
diagnostic  ||| S:627 E:638 ||| JJ
test  ||| S:638 E:643 ||| NN
( ||| S:643 E:644 ||| -LRB-
RDT ||| S:644 E:647 ||| NNP
)  ||| S:647 E:649 ||| -RRB-
results  ||| S:649 E:657 ||| NNS
was  ||| S:657 E:661 ||| VBD
high  ||| S:661 E:666 ||| JJ
in  ||| S:666 E:669 ||| IN
the  ||| S:669 E:673 ||| DT
intervention  ||| S:673 E:686 ||| NN
arm  ||| S:686 E:690 ||| NN
across  ||| S:690 E:697 ||| IN
the  ||| S:697 E:701 ||| DT
three  ||| S:701 E:707 ||| CD
countries ||| S:707 E:716 ||| NNS
,  ||| S:716 E:718 ||| ,
with  ||| S:718 E:723 ||| IN
only  ||| S:723 E:728 ||| RB
4.9 ||| S:728 E:731 ||| CD
%  ||| S:731 E:733 ||| NN
( ||| S:733 E:734 ||| -LRB-
17  ||| S:734 E:737 ||| CD
of  ||| S:737 E:740 ||| IN
344 ||| S:740 E:743 ||| CD
)  ||| S:743 E:745 ||| -RRB-
of  ||| S:745 E:748 ||| IN
RDT-negative  ||| S:748 E:761 ||| JJ
children  ||| S:761 E:770 ||| NNS
prescribed  ||| S:770 E:781 ||| VBN
an  ||| S:781 E:784 ||| DT
ACT ||| S:784 E:787 ||| NNP
.  ||| S:787 E:789 ||| .
Antibiotic  ||| S:789 E:800 ||| JJ
overuse  ||| S:800 E:808 ||| NN
was  ||| S:808 E:812 ||| VBD
more  ||| S:812 E:817 ||| RBR
common ||| S:817 E:823 ||| JJ
:  ||| S:823 E:825 ||| :
0.9 ||| S:825 E:828 ||| CD
%  ||| S:828 E:830 ||| NN
( ||| S:830 E:831 ||| -LRB-
4  ||| S:831 E:833 ||| CD
of  ||| S:833 E:836 ||| IN
446 ||| S:836 E:839 ||| CD
)  ||| S:839 E:841 ||| -RRB-
in  ||| S:841 E:844 ||| IN
Uganda ||| S:844 E:850 ||| NNP
,  ||| S:850 E:852 ||| ,
38.5 ||| S:852 E:856 ||| CD
%  ||| S:856 E:858 ||| NN
( ||| S:858 E:859 ||| -LRB-
114  ||| S:859 E:863 ||| CD
of  ||| S:863 E:866 ||| IN
296 ||| S:866 E:869 ||| CD
)  ||| S:869 E:871 ||| -RRB-
in  ||| S:871 E:874 ||| IN
Burkina  ||| S:874 E:882 ||| NNP
Faso ||| S:882 E:886 ||| NNP
,  ||| S:886 E:888 ||| ,
and  ||| S:888 E:892 ||| CC
44.6 ||| S:892 E:896 ||| CD
%  ||| S:896 E:898 ||| NN
( ||| S:898 E:899 ||| -LRB-
197  ||| S:899 E:903 ||| CD
of  ||| S:903 E:906 ||| IN
442 ||| S:906 E:909 ||| CD
)  ||| S:909 E:911 ||| -RRB-
in  ||| S:911 E:914 ||| IN
Ghana ||| S:914 E:919 ||| NNP
.  ||| S:919 E:921 ||| .
Fever  ||| S:921 E:927 ||| NN
clearance  ||| S:927 E:937 ||| NN
was  ||| S:937 E:941 ||| VBD
high  ||| S:941 E:946 ||| JJ
in  ||| S:946 E:949 ||| IN
both  ||| S:949 E:954 ||| DT
intervention  ||| S:954 E:967 ||| NN
and  ||| S:967 E:971 ||| CC
control  ||| S:971 E:979 ||| NN
arms  ||| S:979 E:984 ||| NNS
at  ||| S:984 E:987 ||| IN
both  ||| S:987 E:992 ||| DT
Day  ||| S:992 E:996 ||| NNP
3  ||| S:996 E:998 ||| CD
( ||| S:998 E:999 ||| -LRB-
97.8 ||| S:999 E:1003 ||| CD
%  ||| S:1003 E:1005 ||| NN
versus  ||| S:1005 E:1012 ||| IN
96.9 ||| S:1012 E:1016 ||| CD
% ||| S:1016 E:1017 ||| NN
,  ||| S:1017 E:1019 ||| ,
P  ||| S:1019 E:1021 ||| NN
=  ||| S:1021 E:1023 ||| SYM
0.17 ||| S:1023 E:1027 ||| CD
)  ||| S:1027 E:1029 ||| -RRB-
and  ||| S:1029 E:1033 ||| CC
Day  ||| S:1033 E:1037 ||| NNP
7  ||| S:1037 E:1039 ||| CD
( ||| S:1039 E:1040 ||| -LRB-
99.2 ||| S:1040 E:1044 ||| NNP
%  ||| S:1044 E:1046 ||| NN
versus  ||| S:1046 E:1053 ||| IN
98.8 ||| S:1053 E:1057 ||| CD
% ||| S:1057 E:1058 ||| NN
,  ||| S:1058 E:1060 ||| ,
P  ||| S:1060 E:1062 ||| NN
=  ||| S:1062 E:1064 ||| SYM
0.17 ||| S:1064 E:1068 ||| CD
) ||| S:1068 E:1069 ||| -RRB-
.  ||| S:1069 E:1071 ||| .
The  ||| S:1071 E:1075 ||| DT
use  ||| S:1075 E:1079 ||| NN
of  ||| S:1079 E:1082 ||| IN
diagnostic  ||| S:1082 E:1093 ||| JJ
tests  ||| S:1093 E:1099 ||| NNS
limits  ||| S:1099 E:1106 ||| VBZ
overuse  ||| S:1106 E:1114 ||| VBN
of  ||| S:1114 E:1117 ||| IN
ACTs ||| S:1117 E:1121 ||| JJ
.  ||| S:1121 E:1123 ||| .
Its  ||| S:1123 E:1127 ||| PRP$
impact  ||| S:1127 E:1134 ||| NN
on  ||| S:1134 E:1137 ||| IN
antibiotic  ||| S:1137 E:1148 ||| JJ
overuse  ||| S:1148 E:1156 ||| NN
and  ||| S:1156 E:1160 ||| CC
on  ||| S:1160 E:1163 ||| IN
fever  ||| S:1163 E:1169 ||| NN
clearance  ||| S:1169 E:1179 ||| NN
is  ||| S:1179 E:1182 ||| VBZ
uncertain ||| S:1182 E:1191 ||| JJ
.  ||| S:1191 E:1193 ||| .
